| 15 | 0 | 7 |
| 下载次数 | 被引频次 | 阅读次数 |
总结闫慧敏教授分期论治儿童IgA血管炎的临证经验。认为急性期病机为火热入血伤络，宜泻火止血，治以自拟青紫凉血方；缓解期病机为气逆血出，宜和气宁血，治以自拟和气宁血方；迁延期病机为阴虚邪伏，宜养络固本，治以自拟养络固本方。同时将消瘀之法贯穿治疗全程。
Abstract：This paper summarizes Professor YAN Huimin's clinical experience in the staged treatment of pediatric IgA vasculitis. It is believed that the pathogenesis in the acute stage is characterized by fire and heat entering the blood and damaging the collaterals, and the treatment should focus on clearing heat and stopping bleeding, using the self-formulated Qingzi Liangxue Formulation （青紫凉血方）. In the remission stage, the pathogenesis is qi rebellion leading to blood extravasation. The treatment principle is to regulate qi and stabilize blood, using the self-formulated Heqi Ningxue Formulation （和气宁血方）. During the protracted stage, the pathogenesis is latent pathogenic factors due to yin deficiency, and the treatment should aim to nourish the collaterals and strengthen the root, with the selfformulated Yangluo Guben Formulation （养络固本方）. Meanwhile, the method of promoting blood stasis resolution is consistently applied throughout the entire treatment process.
[1]XU L, LI Y, WU X. IgA vasculitis update:epidemiology,pathogenesis, and biomarkers[J]. Front Immunol,2022,13:921864. doi:10. 3389/fimmu. 2022. 921864.
[2]中华医学会儿科学分会免疫学组，中华儿科杂志编辑委员会，中国儿童风湿免疫病联盟.中国儿童IgA血管炎诊断与治疗指南（2023）[J].中华儿科杂志，2023,61(12):1067-1076.
[3]ONI L, PLATT C, MARLAIS M, et al. National recommendations for the management of children and young people with IgA vasculitis:a best available evidence, group agreement-based approach[J]. Arch Dis Child,2024,110(1):67-76.
[4]RONKAINEN J, KOSKIMIES O, ALA-HOUHALA M,et al. Early prednisone therapy in Henoch-Sch?nlein purpura:a randomized, double-blind, placebo-controlled trial[J]. J Pediatr,2006,149(2):241-247.
[5]HAHN D, HODSON EM, WILLIS NS,et al. Interventions for preventing and treating kidney disease in HenochSch?nlein purpura(HSP)[J]. Cochrane Database Syst Rev,2015,2015(8):CD005128. doi:10. 1002/14651858.CD005128. pub3.
[6]SRIRANGAN P, SHYAM M, RADHAKRISHNAN V,et al. NLRP3 as a therapeutic target in cyclophosphamideassociated toxicities[J]. Mol Biol Rep,2025,52(1):364.
[7]刘萌，黄岩杰，秦蕾，等.丁樱从湿热伏邪解析过敏性紫癜病因病机[J].中医学报，2017,32(6):960-963.
[8]赵骞，何强，郝静，等.闫慧敏从痈论治腹型过敏性紫癜经验[J].中医杂志，2021,62(17):1488-1491.
[9]周晓莉.刘品莉主任医师治疗过敏性紫癜经验介绍[J].中医杂志，2010,51(S2):104-105.
[10]郝静，闫慧敏.养阴清瘀法治疗儿童过敏性紫癜性肾炎的临床观察[J].环球中医药，2016,9(5):544-548.
[11]NICOARA O,TWOMBLEY K. Immunoglobulin A nephropathy and immunoglobulin A vasculitis[J]. Pediatr Clin North Am,2019,66(1):101-110.
[12]徐荣谦.少阳学说与小儿体质特点[J].中医杂志，2004,45(2):155-156.
[13]尹友生，冷斌，徐庆，等.白茅根多糖对IgA肾病大鼠肾组织学病变及血清白细胞介素2和6的影响[J].中国新药与临床杂志，2014,33(7):520-524.
[14]刘绪林，刘文萍，王丽丽，等.石韦黄酮组分改善糖尿病肾病病理及减轻炎症反应作用研究[J].中国中药杂志，2018,43(11):2352-2357.
[15]JENNETTE JC, FALK RJ,BACON PA, et al. 2012 revised International Chapel Hill consensus conference nomenclature of vasculitides[J]. Arthritis Rheum,2013,65(1):1-11.
[16]韩姗姗，丁樱，代彦林，等.脂质代谢异常对儿童过敏性紫癜肾损伤预测价值的Meta分析[J].中国全科医学，2021,24(32):4137-4144.
[17]虞军勇，杨力群，王子清.儿童过敏性紫癜凝血状态改变及早期抗凝临床实效性探究[J].中国妇幼保健，2014,29(35):5826-5828.
[18]殷海燕．过敏性紫癜的药物治疗进展[J].临床合理用药杂志，2012,5(26):173-174.
[19]何晓峰，赵晓琴，刘晓城，等.丹参对左肾静脉狭窄大鼠肾脏淤血性损伤的保护作用[J].华中科技大学学报（医学版），2008,37(1):26-30.
基本信息:
DOI：10.13288/j.11-2166/r.2025.12.004
中图分类号:R249;R272
引用信息:
[1]刘天翔,赵骞,郝静等.闫慧敏分期论治儿童IgA血管炎经验[J].中医杂志,2025,66(12):1212-1216.DOI:10.13288/j.11-2166/r.2025.12.004.
基金信息:
国家中医药管理局第六批全国名老中医药专家传承工作室建设项目（国中医药人教发[2017]29号）; 北京市属医院科研培育计划项目（PZ2025024）; 首都卫生发展科研专项（首发2022-2-2097）